254 related articles for article (PubMed ID: 34081930)
1. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective.
Kanakis M; Petrou P; Lourida G; Georgalas I
Surv Ophthalmol; 2022; 67(2):388-410. PubMed ID: 34081930
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Neuroimaging Manifestations of Erdheim-Chester Disease: A Review.
Garg N; Lavi ES
J Neuroimaging; 2021 Jan; 31(1):35-44. PubMed ID: 32920940
[TBL] [Abstract][Full Text] [Related]
3. Hypoalphalipoproteinemia and BRAF
Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
[TBL] [Abstract][Full Text] [Related]
4. Erdheim-Chester disease.
Campochiaro C; Tomelleri A; Cavalli G; Berti A; Dagna L
Eur J Intern Med; 2015 May; 26(4):223-9. PubMed ID: 25865950
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
[TBL] [Abstract][Full Text] [Related]
6. [Erdheim-Chester disease-A histiocytic multisystem disease with unusual renal involvement].
Dasdelen S; Büschek F
Internist (Berl); 2020 Sep; 61(9):969-979. PubMed ID: 32785740
[TBL] [Abstract][Full Text] [Related]
7. Erdheim-Chester disease.
Starkebaum G; Hendrie P
Best Pract Res Clin Rheumatol; 2020 Aug; 34(4):101510. PubMed ID: 32305313
[TBL] [Abstract][Full Text] [Related]
8. Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib.
Salama H; Fahed Alzayed M; Alharbi KG; Khattak Z; Omer MH; Tahir L; ALhejazi A
Am J Case Rep; 2022 Feb; 23():e935090. PubMed ID: 35171900
[TBL] [Abstract][Full Text] [Related]
9. Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.
Aggarwal A; Taychert M; Hasanin L; Doll D; Basuino MG; Hasanein H
Oncology (Williston Park); 2023 Jul; 37(7):298-302. PubMed ID: 37499251
[TBL] [Abstract][Full Text] [Related]
10. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
[TBL] [Abstract][Full Text] [Related]
11. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
[TBL] [Abstract][Full Text] [Related]
13. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
[TBL] [Abstract][Full Text] [Related]
14. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
[TBL] [Abstract][Full Text] [Related]
15. An effective treatment in Erdheim Chester disease: vemurafenib: a case report.
Bozan E; Darçın T; Yaman S; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
J Med Case Rep; 2023 Oct; 17(1):426. PubMed ID: 37821987
[TBL] [Abstract][Full Text] [Related]
16. Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports.
Qiao J; Ma R; Peng X; He W
World J Surg Oncol; 2023 Jul; 21(1):233. PubMed ID: 37525276
[TBL] [Abstract][Full Text] [Related]
17. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease.
Saunders IM; Goodman AM; Kurzrock R
Oncologist; 2020 Feb; 25(2):e386-e390. PubMed ID: 32043767
[TBL] [Abstract][Full Text] [Related]
18. Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case series.
Mazor RD; Manevich-Mazor M; Kesler A; Aizenstein O; Eshed I; Jaffe R; Pessach Y; Goldberg I; Sprecher E; Yaish I; Gural A; Ganzel C; Shoenfeld Y
BMC Med; 2014 Dec; 12():221. PubMed ID: 25434739
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the
Oneal PA; Kwitkowski V; Luo L; Shen YL; Subramaniam S; Shord S; Goldberg KB; McKee AE; Kaminskas E; Farrell A; Pazdur R
Oncologist; 2018 Dec; 23(12):1520-1524. PubMed ID: 30120160
[TBL] [Abstract][Full Text] [Related]
20. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
Front Immunol; 2022; 13():918613. PubMed ID: 35874752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
